Advanced search
Publication Cover
Journal of Blood Medicine Volume 15, 2024 - Issue
Submit an article Journal homepage
83
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B

Zoran Igrutinović1 Clinic of Pediatrics, Department of Hemato-Oncology, University Clinical Center of Kragujevac, Kragujevac, Serbia;2 Faculty of Medical Sciences, Department of Pediatrics, University of Kragujevac, Kragujevac, SerbiaORCID Iconhttps://orcid.org/0000-0002-9857-6475View further author information
ORCID Icon,
Hélène Louise Hooimeijer3 Pediatric Hematology, Beatrix Children’s Hospital, University Medical Center Groningen, Groningen, the NetherlandsView further author information
,
Karim Kentouche4 Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Jena, Jena, DeutschlandView further author information
,
Jaco Botha5 Takeda Pharmaceuticals International AG, Zürich, SwitzerlandView further author information
,
Peter L Turecek6 Baxalta Innovations GmbH, Part of Takeda, Vienna, AustriaORCID Iconhttps://orcid.org/0000-0002-6161-1556View further author information
ORCID Icon,
Marta Kokot-Kierepa5 Takeda Pharmaceuticals International AG, Zürich, SwitzerlandView further author information
&
Hanna T Gazda7 Takeda Development Center Americas, Inc., Cambridge, MA, USACorrespondence[email protected]
View further author information
 show all
Pages 113-122 | Received 21 Jul 2023, Accepted 29 Jan 2024, Published online: 05 Mar 2024

References

  • Berntorp E, Fischer K, Hart DP, et al. Haemophilia. Nat Rev Dis Primers. 2021;7(1):45. doi:10.1038/s41572-021-00278-x
  • Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
  • Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol. 2018;11(8):673–683. doi:10.1080/17474086.2018.1489719
  • Turecek PL, Abbühl B, Tangada SD, et al. Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes. Expert Rev Clin Pharmacol. 2015;8(2):163–177. doi:10.1586/17512433.2015.1011126
  • Thomas KB, Urbancik W, Turecek PL, et al. Continuous infusion of FVIII and FIX concentrates: in vitro analysis of clinically relevant parameters. Haemophilia. 1999;5(1):17–25. doi:10.1046/j.1365-2516.1999.00210.x
  • Kavakli K, Smith L, Kuliczkowski K, et al. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B. Haemophilia. 2016;22(3):381–388. doi:10.1111/hae.12878
  • Windyga J, Lissitchkov T, Stasyshyn O, et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre Phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B. Haemophilia. 2014;20(1):15–24. doi:10.1111/hae.12228
  • Collins PW, Quon DVK, Makris M, et al. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. 2018;24(1):104–112. doi:10.1111/hae.13324
  • Valentino LA, Rusen L, Elezovic I, et al. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects. Haemophilia. 2014;20(3):398–406. doi:10.1111/hae.12344
  • Takeda Canada Inc. IMMUNINE® VH: factor IX concentrate (Human). Product Monograph; 2021. Available from: https://assets-dam.takeda.com/raw/upload/v1662721792/legacy-dotcom/siteassets/en-ca/home/what-we-do/our-medicines/product-monographs/immunine-vh/immunine-vh-pm-en.pdf. Accessed September 30, 2022.
  • Takeda Manufacturing Austria AG. IMMUNINE 1200 IU: powder and solvent for solution for injection or infusion. Human blood coagulation factor IX. Package Leaflet; 2020. Available from: https://file.wuxuwang.com/hma/AT_H_0177_002_FinalPL_1of3.pdf. Accessed September 30, 2022.
  • Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774. doi:10.1007/s12325-018-0805-y
  • Negrier C, Voisin S, Baghaei F, et al. Global post-authorization safety surveillance study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate). Blood Coagul Fibrinolysis. 2016;27(5):551–556. doi:10.1097/mbc.0000000000000525
  • Gascoigne EW, Dash CH, Harman C, Wilmot D. A retrospective survey on the safety of Replenate, a high-purity factor VIII concentrate. Pharmacoepidemiol Drug Saf. 2004;13(4):243–252. doi:10.1002/pds.956
  • Gascoigne EW, Dash CH, Harman C, Wilmot D. A retrospective survey on the safety of replenine, a high-purity factor IX concentrate. Pharmacoepidemiol Drug Saf. 2004;13(3):187–195. doi:10.1002/pds.911
  • Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment Guidelines Working Group on behalf of the World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–e47. doi:10.1111/j.1365-2516.2012.02909.x
  • Mancuso ME, Mahlangu JN, Pipe SW. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet. 2021;397(10274):630–640. doi:10.1016/s0140-6736(20)32722-7
  • Collins PW, Young G, Knobe K, et al; Paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized Phase 3 trial. Blood. 2014;124(26):3880–3886. doi:10.1182/blood-2014-05-573055
  • Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369(24):2313–2323. doi:10.1056/NEJMoa1305074
  • Santagostino E, Martinowitz U, Lissitchkov T, et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761–1769. doi:10.1182/blood-2015-09-669234

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.